Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar 8;6(1):8-20.
doi: 10.9740/mhc.2015.01.008. eCollection 2016 Jan.

Pharmacokinetic characteristics of antiepileptic drugs (AEDs)

Marketa Marvanova  1
Affiliations

Pharmacokinetic characteristics of antiepileptic drugs (AEDs)

Marketa Marvanova. Ment Health Clin. .

Abstract

Antiepileptic drugs (AEDs) are routinely prescribed for the management of a variety of neurologic and psychiatric conditions, including epilepsy and epilepsy syndromes. Physiologic changes due to aging, pregnancy, nutritional status, drug interactions, and diseases (ie, those involving liver and kidney function) can affect pharmacokinetics of AEDs. This review discusses foundational pharmacokinetic characteristics of AEDs currently available in the United States, including clobazam but excluding the other benzodiazepines. Commonalities of pharmacokinetic properties of AEDs are discussed in detail. Important differences among AEDs and clinically relevant pharmacokinetic interactions in absorption, distribution, metabolism, and/or elimination associated with AEDs are highlighted. In general, newer AEDs have more predictable kinetics and lower risks for drug interactions. This is because many are minimally or not bound to serum proteins, are primarily renally cleared or metabolized by non-cytochrome P450 isoenzymes, and/or have lower potential to induce/inhibit various hepatic enzyme systems. A clear understanding of the pharmacokinetic properties of individual AEDs is essential in creating a safe and effective treatment plan for a patient.

Keywords: CYP450; UGT; antiepileptic drugs; hepatic metabolism; pharmacokinetic interactions; protein binding.

PubMed Disclaimer

References

    1. Aption.com [Internet]. Aptiom (eslicarbazepine acetate) package insert. Marlborough, (MA): Sunovion Pharmaceuticals Inc; c2013 [cited 2014 Dec 18] Available from: http://www.aptiom.com/Aptiom-Prescribing-Information.pdf
    1. Banzel.com [Internet]. Banzel (rufinamide) package insert. Woodcliff Lake (NJ): Eisai Co, Ltd; c2015 [updated 2015 May; cited 2014 Dec 18] Available from: http://www.banzel.com/hcp/pdfs/BanzelPI.pdf
    1. Food and Drug Administration [Internet]. Carbatrol® (carbamazepine) package insert. Silver Spring (MD): Food and Drug Administration; c.2009 [updated 2009 April; cited 2014 Dec 18] Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020712s030lbl.pdf.
    1. Pfizer.com [Internet]. Cerebyx (fosphenytoin sodium) package insert. New York: Pfizer Labs; [updated 2015 April; accessed 2014 Dec 18] Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=749
    1. AbbVie [Internet]. Depacon. (valproate sodium), prescribing information. North Chicago (IL): AbbVie Inc; [updated 2015 Nov; cited 2014 Dec 18] Available from: http://www.rxabbvie.com/pdf/depacon.pdf